Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute
Portfolio Pulse from
Clearmind Medicine has signed a non-binding term sheet with Dr Glitter Pty Ltd to mutually develop products in the ActivCrystal™ format, focusing on their novel psychedelic MEAI-based alcohol substitute.
December 26, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Clearmind Medicine has entered into a partnership with Dr Glitter Pty Ltd to develop its MEAI-based alcohol substitute in the ActivCrystal™ format, potentially advancing its product offerings.
The partnership with Dr Glitter Pty Ltd is a strategic move for Clearmind Medicine, as it focuses on developing its novel MEAI-based alcohol substitute. This collaboration could enhance product development and market reach, likely having a positive short-term impact on CMND's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90